- Market cap
- Revenue
- Net income
- Cash on hand
- Gross margin
- Net margin
- EPS
- P/E ratio
July 17, 2020 – Acumen Pharmaceuticals, Inc. has engaged three new members as part of its world-class Advisory Board. Cynthia Lemere, Ph.D., Michael Weiner, M.D. and Reisa Sperling, M.D. will join current members… The post ACUMEN WELCOMES NEW MEMBERS TO ITS ADVISORY BOARD first appeared on Acumen Pharmaceuticals.
October 24, 2018 – Acumen Pharmaceuticals, Inc., a preclinical-stage biopharmaceutical company, has held an initial closing on a total $15 million Series A-1 round co-led by PBM Capital Group, Sands Capital Ventures, with participation from new and existing private investors… The post ACUMEN CLOSES SERIES A-1 FOR DEVELOPMENT OF ACU193 first appeared on Acumen Pharmaceuticals.
June 21, 2018 – Acumen Pharmaceuticals, Inc. has hired several former senior members of Eli Lilly & Company’s Alzheimer’s Disease clinical development team. Eric Siemers, M.D., Russell Barton, M.S., Robert Dean, M.D., Ph.D., and Janice Hitchcock, Ph.D. are joining… The post ACUMEN ENGAGES FORMER ELI LILLY ALZHEIMER’S DRUG DEVELOPMENT VETERANS TO SUPPORT THE IND SUBMISSION AND CLINICAL DEVELOPMENT OF ACU193 first appeared on Acumen Pharmaceuticals.
July 28, 2017 – Acumen Pharmaceuticals, Inc. has received a $3.6 million U01 grant from the National Institute of Aging (NIA) to fund the preclinical and early clinical development of ACU193… The post ACUMEN RECEIVES $3.6M GRANT FROM THE NATIONAL INSTITUTE OF AGING TO SUPPORT IND-ENABLING STUDIES FOR ACU193 first appeared on Acumen Pharmaceuticals.
December 31, 2012 – Acumen Pharmaceuticals, Inc. has received exclusive rights from its partner, Merck Sharp & Dohme Corp., (formerly Merck & Co., Inc.), for the joint anti-amyloid beta oligomers (Aβo) immunotherapy program The post ACUMEN RECEIVES EXCLUSIVE RIGHTS TO PRECLINICAL CANDIDATE ACU193 AND ANTI-AMYLOID BETS OLIGOMERS (AβOs) IMMUNOTHERAPY PROGRAM FROM MERCK first appeared on Acumen Pharmaceuticals.